171 related articles for article (PubMed ID: 37934338)
1. Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer.
Finnegan E; Ding W; Ude Z; Terer S; McGivern T; Blümel AM; Kirwan G; Shao X; Genua F; Yin X; Kel A; Fattah S; Myer PA; Cryan SA; Prehn JHM; O'Connor DP; Brennan L; Yochum G; Marmion CJ; Das S
Cell Oncol (Dordr); 2024 Apr; 47(2):533-553. PubMed ID: 37934338
[TBL] [Abstract][Full Text] [Related]
2. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
Chan D; Zheng Y; Tyner JW; Chng WJ; Chien WW; Gery S; Leong G; Braunstein GD; Koeffler HP
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1507-14. PubMed ID: 23824064
[TBL] [Abstract][Full Text] [Related]
3. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
Dovzhanskiy DI; Arnold SM; Hackert T; Oehme I; Witt O; Felix K; Giese N; Werner J
BMC Cancer; 2012 Jun; 12():226. PubMed ID: 22681698
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.
Buckley MT; Yoon J; Yee H; Chiriboga L; Liebes L; Ara G; Qian X; Bajorin DF; Sun TT; Wu XR; Osman I
J Transl Med; 2007 Oct; 5():49. PubMed ID: 17935615
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS-mutant human lung cancer cells.
Peter RM; Sarwar MS; Mostafa SZ; Wang Y; Su X; Kong AN
Mol Carcinog; 2023 Aug; 62(8):1136-1146. PubMed ID: 37144836
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Chien W; Lee DH; Zheng Y; Wuensche P; Alvarez R; Wen DL; Aribi AM; Thean SM; Doan NB; Said JW; Koeffler HP
Mol Carcinog; 2014 Sep; 53(9):722-35. PubMed ID: 23475695
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability.
Zhang C; Guo S; Zhong Q; Zhang Q; Hossain A; Zheng S; Wang G
Pharmaceuticals (Basel); 2019 Dec; 12(4):. PubMed ID: 31817969
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
9. Anticancer clinical efficiency and stochastic mechanisms of belinostat.
El Omari N; Bakrim S; Khalid A; Albratty M; Abdalla AN; Lee LH; Goh KW; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Sep; 165():115212. PubMed ID: 37541175
[TBL] [Abstract][Full Text] [Related]
10. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
Monks A; Hose CD; Pezzoli P; Kondapaka S; Vansant G; Petersen KD; Sehested M; Monforte J; Shoemaker RH
Anticancer Drugs; 2009 Sep; 20(8):682-92. PubMed ID: 19606018
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
[TBL] [Abstract][Full Text] [Related]
12. Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat.
Chang CM; Ramesh KK; Huang V; Gurbani S; Kleinberg LR; Weinberg BD; Shim H; Shu HG
Tomography; 2023 May; 9(3):942-954. PubMed ID: 37218937
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis.
Hamam HJ; Palaniyar N
Biomolecules; 2019 May; 9(5):. PubMed ID: 31083537
[TBL] [Abstract][Full Text] [Related]
15. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
16. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.
Havas AP; Rodrigues KB; Bhakta A; Demirjian JA; Hahn S; Tran J; Scavello M; Tula-Sanchez AA; Zeng Y; Schmelz M; Smith CL
Cancer Biol Ther; 2016 Dec; 17(12):1240-1252. PubMed ID: 27791595
[TBL] [Abstract][Full Text] [Related]
17. CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.
Han XL; Du J; Zheng YD; Dai JJ; Lin SW; Zhang BY; Zhong FB; Lin ZG; Jiang SQ; Wei W; Fang ZY
Biomed Res Int; 2021; 2021():5089371. PubMed ID: 33959656
[TBL] [Abstract][Full Text] [Related]
18. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
[TBL] [Abstract][Full Text] [Related]
19. Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.
Wang L; Chan CEL; Wong AL; Wong FC; Lim SW; Chinnathambi A; Alharbi SA; Lee LS; Soo R; Yong WP; Lee SC; Ho PC; Sethi G; Goh BC
Oncotarget; 2017 Jun; 8(25):41572-41581. PubMed ID: 28157715
[TBL] [Abstract][Full Text] [Related]
20. Belinostat for the treatment of peripheral T-cell lymphomas.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]